Saccharin

Saccharin provides sweetness in small amounts without supplying meaningful calories. The acid and its salts share a sweetening role, but authorized forms and food uses differ between countries. Modern assessments do not consider the historical bladder tumors in rats evidence of a comparable human cancer risk. EFSA updated its acceptable daily intake in 2024 to 9 milligrams per kilogram of body weight, expressed as saccharin itself, and estimated high exposure below that value.

Older reference values may use a different salt basis, so their numbers are not directly interchangeable. Human metabolic findings are mixed. One short trial found no glucose or microbiome changes with saccharin capsules; another found temporarily worse glucose responses with saccharin-and-glucose sachets. A randomized crossover study published in 2026 found no glycemic difference between saccharin, stevia, and sugar periods.

A small three-month study found no average decline in insulin sensitivity, but lacked a control group. These studies do not establish long-term benefit or harm. A cognitive-decline association remains uncertain and its paper was corrected and replaced in 2026. EFSA also identified missing information about potential impurities from one manufacturing process.

Rhode Island excludes artificial sweeteners from covered school foods under nutrition standards; California has a future school-food review framework without a current saccharin-specific ban.

Research reviewed on September 5, 2026 · 12 sources